


REMARKS

This application originally presented Claims 1-25 for prosecution. In the Restriction Requirement mailed September 28, 2001, the Examiner divided the Claims into six Groups, with Group I containing Claims 1-3, Group II containing Claims 4-6, Group III containing Claims 7-11, Group IV containing Claims 12-16, Group V containing Claims 17-20, and Group VI containing Claims 21-25. Applicants hereby elect the Claims in Group II (*i.e.*, Claims 4-6) with traverse, for prosecution in the present case. Applicants reserve the right to file Divisional and/or Continuation application(s) to pursue Claims 1-3 and 7-25 (and/or similar Claims), hereby cancelled as being directed to non-elected Groups. Applicants have also added new Claims 26-37, which are directed toward antibodies. Support for these Claims may be found throughout the Specification (*See e.g.*, pages 5-6, 38-41, 56-57, 63-64, etc.) and no new matter is added in these new Claims.

Should the Examiner believe that a telephone interview would aid in the prosecution of this Application, Applicants encourage the Examiner to call the undersigned at (415) 904-6500.

Dated: 28 November 2001


Kamrin T. MacKnight
Registration No. 38,230

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415-904-6500

APPENDIX I

**MARKED-UP VERSION OF SPECIFICATION'S REPLACEMENT
PARAGRAPHS AND REWRITTEN, ADDED, AND/OR CANCELLED CLAIMS**

The following is a marked-up version of the Specification's replacement paragraphs pursuant to 37 C.F.R. § 1.121(b), as well as a marked-up version of the Claims pursuant to 37 C.F.R. § 1.121(c)(1)(ii) with instructions and markings showing changes made herein to the previous version of record of the Specification and Claims.

IN THE CLAIMS:

Please cancel Claims 1-3 and 7-25, as being elected to non-elected Groups.

Please add new Claims 26-37.

26. The purified antibody of Claim 4, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 28 to 233.

27. The purified antibody of Claim 4, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 23 to 233.

28. The purified antibody of Claim 4, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 1 to 22.

29. The purified antibody of Claim 4, wherein said antibody is directed against SEQ ID NO:4.

30. The purified antibody of Claim 5, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 28 to 233.

31. The purified antibody of Claim 5, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 23 to 233.

32. The purified antibody of Claim 5, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 1 to 22.

33. The purified antibody of Claim 5, wherein said antibody is directed against SEQ ID NO:4.

34. The purified antibody of Claim 6, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 28 to 233.

35. The purified antibody of Claim 6, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 23 to 233.

36. The purified antibody of Claim 6, wherein said antibody is directed against a portion of the amino acid sequence of SEQ ID NO:4, wherein said portion comprises amino acids 1 to 22.

37. The purified antibody of Claim 6, wherein said antibody is directed against SEQ ID NO:4.